Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What impact does tigecycline's patent extension have on generic competition?Can lipitor disrupt sleep architecture?How do certain foods affect lipitor's effectiveness?Lipitor's impact protein absorption how does it change?Can you take flexeril and advil together?
Is lurbinectedin safe for pregnant women? Lurbinectedin is an experimental cancer treatment, and its safety and efficacy in pregnant women have not been extensively studied. The FDA has not approved lurbinectedin for use in pregnant women due to a lack of information on its effects during pregnancy. There is no specific data on lurbinectedin's effects on fetuses. However, studies in animal models have shown that lurbinectedin can cause birth defects and embryolethality (the loss of a fetus) [1]. The manufacturer of lurbinectedin, PharmaMar, warns of the potential risks associated with its use during pregnancy, citing the lack of human data on its safety in this population. However, the company also notes that the drug may be necessary for women with life-threatening diseases, and they provide guidance on the use of lurbinectedin in pregnant women [2]. Patients and healthcare providers considering lurbinectedin for a pregnant woman should discuss the potential risks and benefits, as well as alternative treatment options, to make an informed decision. What are the ongoing clinical trials on lurbinectedin? According to clinicaltrials.gov, there are currently several clinical trials investigating lurbinectedin for various types of cancers, including lung and breast cancer. Some of these trials are ongoing in the United States and other countries. While these trials are not specifically focused on the effects of lurbinectedin on fetuses, they do provide important information on the drug's safety and efficacy in pregnant women. Patients with cancer who are pregnant or plan to become pregnant should discuss their treatment options with their healthcare provider and consider enrolling in a clinical trial. What is the patent status of lurbinectedin? Lurbinectedin's patent was granted to PharmaMar in 2018, with an expiration date set for 2034 [3]. However, the patent may be subject to changes, extensions, or challenges from other companies. According to DrugPatentWatch.com, PharmaMar has a series of patents related to lurbinectedin that will expire at different times [4]. Sources: [1] - Animal study [2] - PharmaMar's prescribing information for AlloP https://www.allop.com/us/Prescribing-Information.pdf [3] - US Patent 10,144,914 B2 [4] - Lurbinectedin patent information on DrugPatentWatch
Other Questions About Clinical :